<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885922</url>
  </required_header>
  <id_info>
    <org_study_id>CG16183A</org_study_id>
    <nct_id>NCT02885922</nct_id>
  </id_info>
  <brief_title>The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients</brief_title>
  <official_title>The Effects of add-on Anti-diabetic Drugs on Inflammation and Energy Homeostasis in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, there are some new classes of anti-diabetic drugs availible in Taiwan. In this
      study, we will observe the change in inflammation and energy homeostasis in type 2 diabetic
      outpatient, who receiving a new anti-diabetic drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, there are some new classes of anti-diabetic drugs availible in Taiwan. However, the
      effects of these anti-diabetic drugs should be further evaluated. Specially, the effects on
      inflammation and energy homeostasis are still not well assessed. In this study, we will
      observe the change in inflammation and energy homeostasis in type 2 diabetic outpatient, who
      receiving a new anti-diabetic drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain-Derived Neurotrophic Factor (BDNF)</measure>
    <time_frame>3 months</time_frame>
    <description>energy homeostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body-composition</measure>
    <time_frame>3 months</time_frame>
    <description>energy homeostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Cell Adhesion Molecule 1 (VCAM-1)</measure>
    <time_frame>3 months</time_frame>
    <description>inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI)</measure>
    <time_frame>12 months</time_frame>
    <description>peripheral artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orexin-A</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Hyperglycemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-diabetic drug</intervention_name>
    <description>Add-on anti-diabetic drug in type 2 diabetic patients</description>
    <other_name>Glucose lowering</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The genetic studies will be applied for efficacy and adverse effect of anti-diabetic drugs.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic patients in Taichung Veterans General Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic outpatient

        Exclusion Criteria:

          -  Refusal of anti-diabetic drugs

          -  Preganacy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>I-Te Lee, MD,PhD</last_name>
    <phone>+886-4-23592525</phone>
    <phone_ext>4006</phone_ext>
    <email>itlee@vghtc.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I Te Lee, MD</last_name>
      <phone>886-4-23741340</phone>
      <email>itlee@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>I Te Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data (IPD) available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

